Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00073468 | Prostate | BPH | regulation of mitotic cell cycle | 115/3107 | 457/18723 | 1.52e-06 | 2.62e-05 | 115 |
GO:000647010 | Prostate | BPH | protein dephosphorylation | 78/3107 | 281/18723 | 1.53e-06 | 2.63e-05 | 78 |
GO:190357317 | Prostate | BPH | negative regulation of response to endoplasmic reticulum stress | 21/3107 | 44/18723 | 1.56e-06 | 2.67e-05 | 21 |
GO:003109810 | Prostate | BPH | stress-activated protein kinase signaling cascade | 70/3107 | 247/18723 | 2.32e-06 | 3.79e-05 | 70 |
GO:003196016 | Prostate | BPH | response to corticosteroid | 52/3107 | 167/18723 | 2.34e-06 | 3.81e-05 | 52 |
GO:00071628 | Prostate | BPH | negative regulation of cell adhesion | 82/3107 | 303/18723 | 2.51e-06 | 4.04e-05 | 82 |
GO:005140310 | Prostate | BPH | stress-activated MAPK cascade | 68/3107 | 239/18723 | 2.77e-06 | 4.41e-05 | 68 |
GO:000646916 | Prostate | BPH | negative regulation of protein kinase activity | 62/3107 | 212/18723 | 2.81e-06 | 4.45e-05 | 62 |
GO:200027815 | Prostate | BPH | regulation of DNA biosynthetic process | 37/3107 | 106/18723 | 3.52e-06 | 5.48e-05 | 37 |
GO:00330447 | Prostate | BPH | regulation of chromosome organization | 56/3107 | 187/18723 | 3.78e-06 | 5.81e-05 | 56 |
GO:190336315 | Prostate | BPH | negative regulation of cellular protein catabolic process | 29/3107 | 75/18723 | 3.92e-06 | 5.96e-05 | 29 |
GO:003367315 | Prostate | BPH | negative regulation of kinase activity | 67/3107 | 237/18723 | 4.15e-06 | 6.25e-05 | 67 |
GO:190305115 | Prostate | BPH | negative regulation of proteolysis involved in cellular protein catabolic process | 26/3107 | 64/18723 | 4.20e-06 | 6.31e-05 | 26 |
GO:00512715 | Prostate | BPH | negative regulation of cellular component movement | 94/3107 | 367/18723 | 6.18e-06 | 9.00e-05 | 94 |
GO:00324358 | Prostate | BPH | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 17/3107 | 35/18723 | 1.15e-05 | 1.56e-04 | 17 |
GO:20001465 | Prostate | BPH | negative regulation of cell motility | 91/3107 | 359/18723 | 1.34e-05 | 1.76e-04 | 91 |
GO:00074924 | Prostate | BPH | endoderm development | 28/3107 | 77/18723 | 2.21e-05 | 2.67e-04 | 28 |
GO:005134616 | Prostate | BPH | negative regulation of hydrolase activity | 94/3107 | 379/18723 | 2.46e-05 | 2.94e-04 | 94 |
GO:005116815 | Prostate | BPH | nuclear export | 46/3107 | 154/18723 | 2.86e-05 | 3.32e-04 | 46 |
GO:00400135 | Prostate | BPH | negative regulation of locomotion | 96/3107 | 391/18723 | 3.11e-05 | 3.54e-04 | 96 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP1 | SNV | Missense_Mutation | | c.1516N>A | p.Cys506Ser | p.C506S | O94782 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
USP1 | SNV | Missense_Mutation | | c.1058N>T | p.Ser353Phe | p.S353F | O94782 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
USP1 | SNV | Missense_Mutation | novel | c.127C>G | p.Gln43Glu | p.Q43E | O94782 | protein_coding | tolerated(0.18) | benign(0.104) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | rs772351967 | c.962N>G | p.Tyr321Cys | p.Y321C | O94782 | protein_coding | tolerated(0.19) | benign(0) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.670N>G | p.Lys224Glu | p.K224E | O94782 | protein_coding | tolerated(0.82) | benign(0.033) | TCGA-AN-A0AL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
USP1 | SNV | Missense_Mutation | | c.1881N>T | p.Leu627Phe | p.L627F | O94782 | protein_coding | deleterious(0.04) | benign(0.376) | TCGA-BH-A0C0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
USP1 | SNV | Missense_Mutation | novel | c.219G>C | p.Lys73Asn | p.K73N | O94782 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USP1 | insertion | In_Frame_Ins | novel | c.395_396insCGTTACTTCCAA | p.Asp131_Lys132insAsnValThrSer | p.D131_K132insNVTS | O94782 | protein_coding | | | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
USP1 | insertion | Frame_Shift_Ins | novel | c.2072_2073insCTGCAGGTGCCCACCACCACGCCCGGCTAATTTTTTGTATTTT | p.Ser692CysfsTer15 | p.S692Cfs*15 | O94782 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
USP1 | SNV | Missense_Mutation | novel | c.748G>A | p.Glu250Lys | p.E250K | O94782 | protein_coding | tolerated(0.21) | benign(0.341) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-5510 | CHEMBL578741 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CLOFENOXYDE | CLOFENOXYDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GW7074 | CHEMBL72365 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | CETRIMIDE | CETRIMIDE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BENZIODARONE | BENZIODARONE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | GNF-PF-4579 | CHEMBL584626 | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | AMYLMETACRESOL | AMYLMETACRESOL | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | BEXAROTENE | BEXAROTENE | |
7398 | USP1 | DNA REPAIR, PROTEASE, ENZYME | | DITHIAZANINE | DITHIAZANINE | |